Tag Archives: panel

RESI San Diego: Venture Philanthropy Panel Announcement

18 May

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Investors in venture philanthropy, such as foundations and specific family offices, have deep expertise that is often overlooked. Many venture philanthropic groups have a specific mission in a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

LSN is pleased to announce a panel of five expert venture philanthropic investors for the RESI San Diego Conference on June 19th. The audience will have an exclusive opportunity to hear from:

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals. Be sure not to lose track of the mission in life science, and not miss the opportunity of hearing how these panelists can help you with your philanthropic mission.

Register by Friday to save $200, be the first to request investor meetings on partnering, and hear from this fantastic panel!

Tags: , , , ,

RESI San Diego Panel Announcement – Diagnostic Investors

4 May

By Michael Quigley, VP of Market Research, LSN

mike-2

Fundraising for diagnostics companies, like most early stage healthcare technologies, is no easy task. A relative lack of a thriving M&A/IPO exit environment compared to other life science sectors along with high profile flops in the space has made some investors wary. However there exists a significant need for advancement in the field of diagnostics. From pharma companies wanting novel biomarkers to more accurately stratify patients for clinical trials, to the rise of personalized therapies via genomic testing, there’s a growing need for more accurate diagnostics and in many disease areas they do not currently exist.

In addition, many traditionally software or technology focused VCs and major strategics are looking to utilize their expertise to advance bioinformatic breakthroughs. While some these “new” healthcare investors have learned the hard way the difference between healthcare and consumer tech, as they continue to learn they will likely represent an increase of value added capital to the space.

In this session, we will hear from 5 Investors including VCs, large corporations and angels with experience and intent to invest in early stage diagnostics companies. The speakers will cover the types of investments they are looking to make and share insights they have learned working within the space. For any entrepreneur looking to raise capital for a diagnostic technology this is a must attend panel. Look below to see the speakers for yourself. We hope to see you in San Diego.

Tags: , , , , , , ,

RESI Panel Announcement – Diagnostic Investors

30 Mar

By Lucy Parkinson, Director of Research, LSN

Diagnostics is a challenging landscape for fundraising and commercialization; however, the sector attracts interest and backing from a wide variety of stakeholders. There are many unmet needs in the sector, from finding new disease biomarkers to improving monitoring of progressive diseases.

The range of diagnostic investors attending RESI on MaRS next Tuesday provide testament to this varied landscape, with interest in novel diagnostic technologies coming from major pharma and device companies, diagnostic service providers, venture investors, and government organizations. RESI will bring the diagnostics world together for a panel discussion, moderated by Bob Williams, Vice President, Business Development and Innovation – Bracco Diagnostics, and featuring:

These investors will introduce their own specific angle on the diagnostics sector, and will cover what they look for in an investment opportunity in this sector. Panelists will also provide advice on how to make a new diagnostic catch their attention as an investable product. If you’d like to hear the advice of these experts at RESI, there’s still time to sign up.

Tags: , , , , , ,

RESI@MaRS Panel Announcement: Early Stage Therapeutic Investors

9 Mar

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09

This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.

Tags: , , , , , ,

RESI on MaRS Panel Announcement: Corporate Venture Capital

2 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the second time and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by John Gustofson, Senior Director, Abbvie Ventures, this panel will feature:

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , , , , , , ,

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

Tags: , , , , , , ,

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

Tags: , , , , , , ,

← Older Entries
Newer Entries →